Medline S-1 Filing Registers a 60 Million Share Secondary Sale

An S-1 filing is not only for first-time IPOs; companies also use it to register shares that existing owners want to sell, and on May 20, 2026, Medline Inc. filed one to register a 60 million share secondary offering by its private equity sponsors and founding family.

What happened

Medline, which trades on Nasdaq under the symbol MDLN, filed a Form S-1 on May 20, 2026 covering 60,000,000 shares of Class A common stock, with an underwriters’ option for 9,000,000 more. The sellers are existing holders: affiliates of Blackstone, Carlyle and Hellman & Friedman, and members of the Mills family. The prospectus states that Medline will not receive any proceeds from the shares sold by the selling stockholders.

The last reported sale price cited in the filing was $37.70 per share on May 19, 2026. At that price, the base offering of 60 million shares would be worth roughly $2.3 billion before any option exercise, though the final price is set at pricing.

Goldman Sachs and Morgan Stanley serve as global coordinators, BofA Securities and J.P. Morgan as joint bookrunning managers, and Blackstone Capital Markets as a co-manager.

Medline describes itself as the largest provider of medical-surgical products and supply chain solutions across the continuum of care. It reports two segments: Medline Brand, with about 190,000 products, and Supply Chain Solutions, with about 145,000 products. For the year ended December 31, 2025, the company reported net sales of $28.4 billion, net income of $1.2 billion and adjusted EBITDA of $3.5 billion.

How it works

Medline uses an umbrella structure common among sponsor-backed companies. Pre-IPO owners hold common units in an operating partnership together with Class B shares that carry votes. To sell, they exchange units for Class A shares, which are the shares that trade on Nasdaq, and then sell those shares in the registered offering.

Because the shares come from existing owners, the offering does not add new money to the company. It does, however, increase the public float, the number of shares available to outside investors, and it reduces the sponsors’ economic stakes. Medline remains a controlled company, with the principal stockholders retaining significant ownership through their units and Class B stock.

Secondary offerings like this one follow a predictable cycle after a sponsor-backed IPO. Once lock-up restrictions lapse, sponsors sell in large blocks through underwritten deals, often at a small discount to the market price, to return capital to their funds.

Key terms

• Secondary offering: A sale of existing shares by current holders rather than new shares by the company.
• Selling stockholders: Existing owners named in the prospectus who sell their shares.
• Common units: Interests in the operating partnership that can be exchanged for Class A shares.
• Underwriters’ option: The right to buy extra shares, here 9,000,000, to cover demand.
• Controlled company: A listed company where a holder or group controls a majority of voting power.

FAQ

Why would a listed company file an S-1 filing instead of using a shelf?

Newer public companies may not yet be eligible for short-form shelf registration on Form S-3, so they register resales on Form S-1 until they meet the S-3 requirements.

Does Medline get any money from this sale?

No. The prospectus says all proceeds go to the selling stockholders.

What happens to sponsor control?

The sponsors’ stakes shrink, but the company remains controlled by its principal stockholders according to the filing.

What should readers watch?

The final pricing and discount to market, whether the underwriters exercise their option, and future filings showing how much the sponsors still own after the sale.